BACKGROUND: Since ganciclovir-resistant cytomegalovirus (CMV) disease was initially
described in a patient with acquired immunodeficiency syndrome (AIDS) in 1986, the …

BACKGROUND: Cytomegalovirus (CMV) disease is a major cause of morbidity and mortality
after lung transplantation despite ganciclovir prophylaxis. The emergence of ganciclovir …

Background. Cytomegalovirus (CMV) resistance to ganciclovir has become increasingly
common in acquired immu; nodeficiency syndrome patients but has only rarely been …

In the era of more aggressive immunosuppressive regimens and antiviral prophylaxis,
ganciclovir-resistant cytomegalovirus (CMV) has been recognized as an important clinical …

Background Cytomegalovirus (CMV) infection results in significant morbidity and mortality in
lung transplant recipients. Ganciclovir (GCV) has dramatically reduced complications …

Background. Ganciclovir‐resistant (GCV‐R) cytomegalovirus (CMV) is now being reported
with increasing frequency in solid organ transplant recipients. Objective. To describe the …

Clinical consequences of ganciclovir resistant cytomegalovirus (CMV) infections were
studied during 2 large prophylactic trials consisting of 100 days of valganciclovir or …

Background The rate of cytomegalovirus (CMV) mutations conferring ganciclovir resistance
was assessed in a trial comparing intravenous ganciclovir and oral valganciclovir for …

Background. The incidence and clinical and virologic aspects of ganciclovir-resistant
cytomegalovirus (CMV) disease have not been well-characterized in heart transplant …

The resistance of cytomegalovirus (CMV) to ganciclovir is a factor in therapeutic failure and
disease progression. The clinical significance of such resistance in solid-organ …